Reported about 1 month ago
Billionaire hedge fund manager Israel Englander has quietly acquired a significant stake in Summit Therapeutics, a biotech company with a lung cancer drug showing promising trial results. Summit's ivonescimab demonstrated impressive efficacy compared to Merck's Keytruda, boosting investor interest. However, experts advise caution due to ongoing uncertainties surrounding further trials and market acceptance, highlighting that Summit stock might be more of a speculative trade rather than a solid investment opportunity at this moment.
Source: YAHOO